Physician profile
Eugene Lin
NPI 1972595726
$1,143.06
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $87.20 · 2021: $554 · 2022: $57.88 · 2023: $37.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $648.91 | 2021-2023 | Surpass Evolve |
| Takeda Pharmaceuticals U.S.A., INC. | $73.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.85 | 2019-2020 | |
| Novo Nordisk INC | $59.10 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $54.64 | 2019 | |
| Lilly USA, LLC | $38.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.75 | 2019 | |
| Kaleo, INC. | $34.49 | 2019 | |
| Neos Therapeutics, Lp | $27.15 | 2020 | |
| Sanofi Pasteur INC. | $19.74 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $19.51 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.83 | 2019 | |
| Adlon Therapeutics L.P. | $15.15 | 2019 | |
| Shire North American Group INC | $13.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.68 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.